These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38839719)

  • 1. Topical Solution for Retinal Delivery: Bevacizumab and Ranibizumab Eye Drops in Anti-Aggregation Formula (AAF) in Rabbits.
    Giannos SA; Kraft ER; Luisi JD; Schmitz-Brown ME; Reffatto V; Merkley KH; Gupta PK
    Pharm Res; 2024 Jun; 41(6):1247-1256. PubMed ID: 38839719
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topical Delivery of Anti-VEGF Drugs to the Ocular Posterior Segment Using Cell-Penetrating Peptides.
    de Cogan F; Hill LJ; Lynch A; Morgan-Warren PJ; Lechner J; Berwick MR; Peacock AFA; Chen M; Scott RAH; Xu H; Logan A
    Invest Ophthalmol Vis Sci; 2017 May; 58(5):2578-2590. PubMed ID: 28494491
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Theoretical Insights into the Retinal Dynamics of Vascular Endothelial Growth Factor in Patients Treated with Ranibizumab, Based on an Ocular Pharmacokinetic/Pharmacodynamic Model.
    Hutton-Smith LA; Gaffney EA; Byrne HM; Caruso A; Maini PK; Mazer NA
    Mol Pharm; 2018 Jul; 15(7):2770-2784. PubMed ID: 29734810
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitreomacular Interface after Anti-Vascular Endothelial Growth Factor Injections in Neovascular Age-Related Macular Degeneration.
    Veloso CE; Kanadani TM; Pereira FB; Nehemy MB
    Ophthalmology; 2015 Aug; 122(8):1569-72. PubMed ID: 26038338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SYSTEMIC PHARMACOKINETICS AND PHARMACODYNAMICS OF INTRAVITREAL AFLIBERCEPT, BEVACIZUMAB, AND RANIBIZUMAB.
    Avery RL; Castellarin AA; Steinle NC; Dhoot DS; Pieramici DJ; See R; Couvillion S; Nasir MA; Rabena MD; Maia M; Van Everen S; Le K; Hanley WD
    Retina; 2017 Oct; 37(10):1847-1858. PubMed ID: 28106709
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal anti-VEGF injections for treating wet age-related macular degeneration: a systematic review and meta-analysis.
    Ba J; Peng RS; Xu D; Li YH; Shi H; Wang Q; Yu J
    Drug Des Devel Ther; 2015; 9():5397-405. PubMed ID: 26451092
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Mechanistic Model of the Intravitreal Pharmacokinetics of Large Molecules and the Pharmacodynamic Suppression of Ocular Vascular Endothelial Growth Factor Levels by Ranibizumab in Patients with Neovascular Age-Related Macular Degeneration.
    Hutton-Smith LA; Gaffney EA; Byrne HM; Maini PK; Schwab D; Mazer NA
    Mol Pharm; 2016 Sep; 13(9):2941-50. PubMed ID: 26726925
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histological and Immunohistochemical Retinal Changes Following the Intravitreal Injection of Aflibercept, Bevacizumab and Ranibizumab in Newborn Rabbits.
    Cam D; Berk AT; Micili SC; Kume T; Ergur BU; Yilmaz O
    Curr Eye Res; 2017 Feb; 42(2):315-322. PubMed ID: 27314606
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Posterior vitreous detachment with microplasmin alters the retinal penetration of intravitreal bevacizumab (Avastin) in rabbit eyes.
    Goldenberg DT; Giblin FJ; Cheng M; Chintala SK; Trese MT; Drenser KA; Ruby AJ
    Retina; 2011 Feb; 31(2):393-400. PubMed ID: 21099453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alternating Bi-Weekly Intravitreal Ranibizumab and Bevacizumab for Refractory Neovascular Age-Related Macular Degeneration with Pigment Epithelial Detachment
    Witkin AJ; Rayess N; Garg SJ; Maguire JI; Storey P; Kaiser RS; Hsu J; Vander JF; Ho AC
    Semin Ophthalmol; 2017; 32(3):309-315. PubMed ID: 26337539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and retinal distribution of ranibizumab, a humanized antibody fragment directed against VEGF-A, following intravitreal administration in rabbits.
    Gaudreault J; Fei D; Beyer JC; Ryan A; Rangell L; Shiu V; Damico LA
    Retina; 2007; 27(9):1260-6. PubMed ID: 18046235
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Three-Dimensional Transport Model for Intravitreal and Suprachoroidal Drug Injection.
    Zhang Y; Bazzazi H; Lima E Silva R; Pandey NB; Green JJ; Campochiaro PA; Popel AS
    Invest Ophthalmol Vis Sci; 2018 Oct; 59(12):5266-5276. PubMed ID: 30383198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic Biodistribution and Intravitreal Pharmacokinetic Properties of Bevacizumab, Ranibizumab, and Aflibercept in a Nonhuman Primate Model.
    Christoforidis JB; Briley K; Binzel K; Bhatia P; Wei L; Kumar K; Knopp MV
    Invest Ophthalmol Vis Sci; 2017 Nov; 58(13):5636-5645. PubMed ID: 29094168
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye).
    Stewart MW; Rosenfeld PJ; Penha FM; Wang F; Yehoshua Z; Bueno-Lopez E; Lopez PF
    Retina; 2012 Mar; 32(3):434-57. PubMed ID: 22374154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retinal function and morphology in rabbit after intravitreal injection of VEGF inhibitors.
    Myers AC; Lövestam Adrian M; Bruun A; Ghosh F; Andréasson S; Ponjavic V
    Curr Eye Res; 2012 May; 37(5):399-407. PubMed ID: 22510009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment regimens for administration of anti-vascular endothelial growth factor agents for neovascular age-related macular degeneration.
    Li E; Donati S; Lindsley KB; Krzystolik MG; Virgili G
    Cochrane Database Syst Rev; 2020 May; 5(5):CD012208. PubMed ID: 32374423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD.
    Avery RL; Castellarin AA; Steinle NC; Dhoot DS; Pieramici DJ; See R; Couvillion S; Nasir MA; Rabena MD; Le K; Maia M; Visich JE
    Br J Ophthalmol; 2014 Dec; 98(12):1636-41. PubMed ID: 25001321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of responses to intravitreal bevacizumab, ranibizumab, or aflibercept injections for neovascular age-related macular degeneration.
    Park DH; Sun HJ; Lee SJ
    Int Ophthalmol; 2017 Oct; 37(5):1205-1214. PubMed ID: 27826933
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of intravitreal ranibizumab (Lucentis).
    Bakri SJ; Snyder MR; Reid JM; Pulido JS; Ezzat MK; Singh RJ
    Ophthalmology; 2007 Dec; 114(12):2179-82. PubMed ID: 18054637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aqueous vascular endothelial growth factor and ranibizumab concentrations after monthly and bimonthly intravitreal injections of ranibizumab for age-related macular degeneration.
    Wang X; Sawada T; Kakinoki M; Miyake T; Kawamura H; Saishin Y; Liu P; Ohji M
    Graefes Arch Clin Exp Ophthalmol; 2014 Jul; 252(7):1033-9. PubMed ID: 24196779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.